Keyword: University of Oxford
Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.
The series A round will bankroll efforts to develop antibodies that treat autoimmune diseases by stimulating specific immune cell signals.
Working with Sensyne Health, Evotec will support researchers at the university as they generate data to show the commercial viability of projects.
The collaboration will analyze MRI data from 35,000 multiple sclerosis patients and results from IL-17 inhibitor trials.
OxStem named Georg Terstappen chief scientific officer, to help lead its six programs aiming to stimulate stem-cell repair mechanisms in the body.
Brand-new U.K. biotech Izana has kicked off a phase 2a trial of anti-GM-CSF antibody namilumab in ankylosing spondylitis.
Modus Therapeutics raised over 140 million Swedish krona, or about $15.7 million, to advance clinical studies of sevuparin in sickle cell disease.
OVM will use the $12.5 million investment to take vaccines against cervical cancer and other solid tumors into the clinic.
European researchers discovered how drugs bind to the enzyme DHODH, which could lead to more selective cancer drugs.
Nightstar will complete a phase 3 trial of its choroideremia gene therapy and advance two other eye disease candidates through early-stage studies.